Health Trials

Complement 3 Glomerulopathy (C3G)

1

Review clinical trials related to Complement 3 Glomerulopathy (C3G). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Chinese Adults With Kidney Disease

This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).

Participants needed: 30
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: ADARx Pharmaceuticals, Inc.Updated: Jun 25, 2026Locations: 10
Eligibility criteria

Mean eGFR greater than or equal to 30 mL/min/1.73m2 [+4]

Previous kidney transplant or major solid organ transplant [+6]

Read more